Immuntherapie des HNSCC

详细信息    查看全文

• 作者：Dr. J. Döscher ; C.-J. Busch ; P. J. Schuler ; S. Laban
• 关键词：SchlüsselwörterBiomarker ; PD ; 1 ; Rezeptor ; CTLA ; 4 ; Kopf ; Hals ; Tumoren ; Immunmodulation
• 刊名：HNO
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：64
• 期：10
• 页码：700-707
• 全文大小：265 KB
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Otorhinolaryngology
  Neurosurgery
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1433-0458
• 卷排序：64

文摘

BackgroundImmunotherapy remains a hot topic with an endless stream of new upcoming clinical trials. The results of studies to date are promising for second-line palliative treatment of head and neck squamous cell carcinoma (HNSCC). The next step is testing these strategies in randomized trials for first-line and curative treatment in an adjuvant, neoadjuvant, and primarily nonsurgical setting. So far, established biomarkers have not proven reliable enough to predict response rates precisely.